A pioneering drug developed to treat women with inherited cancers can
also benefit men with advanced prostate cancer, a major new clinical
trial concludes.
The trial is a milestone in cancer treatment as the first to show
the benefits of 'precision medicine' in prostate cancer with treatment
matched to the particular genetic characteristics of a man's tumour.
Olaparib, the world's first drug to reach the market targeted
against inherited cancer mutations, was found to benefit as many as a
third of patients with prostate cancer, including many who did not
inherit cancer genes but whose tumours had acquired defects in DNA
repair.
The trial, called TOPARP-A, received support from a wide range of
funders including Cancer Research UK, the Prostate Cancer Foundation,
Stand Up To Cancer, Prostate Cancer UK and the Movember Foundation.
No comments:
Post a Comment